Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 1
1970 1
1975 2
1976 1
1985 1
1988 1
1991 2
1994 1
1995 2
1996 1
1997 4
1998 2
1999 7
2000 4
2001 4
2002 3
2003 7
2004 6
2005 7
2006 6
2007 8
2008 7
2009 7
2010 5
2011 2
2012 6
2013 12
2014 17
2015 8
2016 11
2017 9
2018 5
2019 5
2020 10
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

169 results
Results by year
Filters applied: . Clear all
Page 1
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: hodge jw. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.
Consensus guidelines for the detection of immunogenic cell death.
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L. Kepp O, et al. Among authors: hodge jw. Oncoimmunology. 2014 Dec 13;3(9):e955691. doi: 10.4161/21624011.2014.955691. eCollection 2014 Oct. Oncoimmunology. 2014. PMID: 25941621 Free PMC article. Review.
Natural Born Killers: NK Cells in Cancer Therapy.
Franks SE, Wolfson B, Hodge JW. Franks SE, et al. Among authors: hodge jw. Cancers (Basel). 2020 Jul 31;12(8):2131. doi: 10.3390/cancers12082131. Cancers (Basel). 2020. PMID: 32751977 Free PMC article. Review.
Overcoming hypoxia-induced functional suppression of NK cells.
Solocinski K, Padget MR, Fabian KP, Wolfson B, Cecchi F, Hembrough T, Benz SC, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW. Solocinski K, et al. Among authors: hodge jw. J Immunother Cancer. 2020 Apr;8(1):e000246. doi: 10.1136/jitc-2019-000246. J Immunother Cancer. 2020. PMID: 32345623 Free PMC article.
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C. Friedman J, et al. Among authors: hodge jw. Clin Cancer Res. 2020 Feb 1;26(3):679-689. doi: 10.1158/1078-0432.CCR-19-2209. Epub 2019 Oct 23. Clin Cancer Res. 2020. PMID: 31645352 Free PMC article.
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM. Giles AJ, et al. Among authors: hodge jw. JCI Insight. 2019 Oct 17;4(20):e130688. doi: 10.1172/jci.insight.130688. JCI Insight. 2019. PMID: 31536478 Free PMC article.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT. Robbins Y, et al. Among authors: hodge jw. Elife. 2020 Jul 7;9:e54854. doi: 10.7554/eLife.54854. Elife. 2020. PMID: 32633234 Free PMC article.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: hodge jw. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article.
169 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page